Policy & Regulation
India's Bharat Biotech COVID-19 vaccine shows 81% interim efficacy in late stage trials
3 March 2021 -

Indian biotechnology company Bharat Biotech said on 3 March 2021 that its domestic COVID-19 vaccine has shown an interim vaccine efficacy of 81% in late-stage clinical trials, Reuters news agency reported on Wednesday.

Reportedly, these trials involved 25,800 participants and were conducted in partnership with the Indian government's medical research body.



Related Headlines